Brokerages Set Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Target Price at $5.40

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and four have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $5.40.

Several equities research analysts recently commented on the company. Oppenheimer assumed coverage on Inhibikase Therapeutics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $5.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Tuesday, April 21st. Finally, LADENBURG THALM/SH SH assumed coverage on Inhibikase Therapeutics in a research report on Wednesday, March 4th. They set a “buy” rating and a $4.00 target price on the stock.

Institutional Investors Weigh In On Inhibikase Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in IKT. BNP Paribas Financial Markets boosted its position in shares of Inhibikase Therapeutics by 70.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,640 shares of the company’s stock valued at $25,000 after purchasing an additional 6,458 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Inhibikase Therapeutics during the 1st quarter valued at about $26,000. Sanctuary Advisors LLC bought a new stake in shares of Inhibikase Therapeutics during the 4th quarter valued at about $26,000. Renaissance Technologies LLC bought a new stake in shares of Inhibikase Therapeutics during the 1st quarter valued at about $28,000. Finally, XTX Topco Ltd bought a new stake in shares of Inhibikase Therapeutics during the 4th quarter valued at about $42,000. Institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Trading Up 1.9%

NASDAQ IKT opened at $1.91 on Friday. The business’s 50-day moving average price is $1.78 and its two-hundred day moving average price is $1.76. Inhibikase Therapeutics has a 12 month low of $1.33 and a 12 month high of $2.26. The firm has a market capitalization of $251.52 million, a PE ratio of -4.43 and a beta of 0.92.

Inhibikase Therapeutics (NASDAQ:IKT) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). As a group, analysts forecast that Inhibikase Therapeutics will post -0.4 earnings per share for the current fiscal year.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.